Cargando…

Clinical Utility of Circulating Tumor Cells in Patients With Esophageal Cancer

BACKGROUND: As one of the most aggressive gastrointestinal tract cancers, esophageal carcinoma (EC) had the tenth morbidity and sixth mortality rate globally in 2020. This study was conducted to investigate whether circulating tumor cells (CTCs) could be used as diagnostic and prognostic tools for p...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yang, Wang, Zhenxing, Fu, Rao, Wang, Shuang, Zhang, Tingting, Tian, Xudong, Yang, Dawei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977550/
https://www.ncbi.nlm.nih.gov/pubmed/35387131
http://dx.doi.org/10.3389/fonc.2022.828368
_version_ 1784680789924904960
author Li, Yang
Wang, Zhenxing
Fu, Rao
Wang, Shuang
Zhang, Tingting
Tian, Xudong
Yang, Dawei
author_facet Li, Yang
Wang, Zhenxing
Fu, Rao
Wang, Shuang
Zhang, Tingting
Tian, Xudong
Yang, Dawei
author_sort Li, Yang
collection PubMed
description BACKGROUND: As one of the most aggressive gastrointestinal tract cancers, esophageal carcinoma (EC) had the tenth morbidity and sixth mortality rate globally in 2020. This study was conducted to investigate whether circulating tumor cells (CTCs) could be used as diagnostic and prognostic tools for patients with EC. METHODS: Peripheral blood samples were collected from 129 patients newly diagnosed with EC, 17 individuals with benign diseases, and 75 healthy donors for CTC analysis using the negative enrichment-fluorescence in situ hybridization (NE-FISH) approach. The relationship between CTCs (counts and karyotypes) and clinicopathological features was then investigated. Moreover, overall survival (OS) and progression-free survival (PFS) were analyzed to evaluate the predictive value of CTCs. RESULTS: The detection of CTCs using the NE-FISH approach helped in differentiating patients with EC from benign or healthy controls at a threshold of 2 per 3.2 ml peripheral blood with a sensitivity and specificity of 70.54% and 96.74%, respectively (area under the curve = 0.826, 95% CI 0.770–0.874, p < 0.001). The CTC count was associated with tumor depth (p = 0.012), but there was no correlation with other clinicopathological characteristics. Furthermore, the proportion of CTCs with chromosome 7 triploidy was linked to distant metastasis (p = 0.033) and TNM stage (p = 0.002). The OS was significantly shorter for patients with CTCs ≥ 3 than for those with CTCs < 3. Univariate analysis revealed that sex, vascular invasion, distant metastasis, tumor depth, lymph node metastasis, and TNM stage were the significant prognostic factors for patients with EC. Multivariate analysis demonstrated that distant metastasis (hazard ratio (HR) 3.262, 95% CI 1.671–6.369, p = 0.001 for PFS; HR 3.759, 95% CI 1.867–7.571, p < 0.001 for OS) was a significant prognostic factor for patients with EC. CONCLUSIONS: Detection of CTCs using NE-FISH could be helpful in the diagnosis of EC. The proportion of CTCs with chromosome 7 triploidy was related to distant metastasis and TNM stage. Patients with CTCs ≥ 3 had short OS, while distant metastasis was an independent factor indicating a poor prognosis for patients with EC.
format Online
Article
Text
id pubmed-8977550
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89775502022-04-05 Clinical Utility of Circulating Tumor Cells in Patients With Esophageal Cancer Li, Yang Wang, Zhenxing Fu, Rao Wang, Shuang Zhang, Tingting Tian, Xudong Yang, Dawei Front Oncol Oncology BACKGROUND: As one of the most aggressive gastrointestinal tract cancers, esophageal carcinoma (EC) had the tenth morbidity and sixth mortality rate globally in 2020. This study was conducted to investigate whether circulating tumor cells (CTCs) could be used as diagnostic and prognostic tools for patients with EC. METHODS: Peripheral blood samples were collected from 129 patients newly diagnosed with EC, 17 individuals with benign diseases, and 75 healthy donors for CTC analysis using the negative enrichment-fluorescence in situ hybridization (NE-FISH) approach. The relationship between CTCs (counts and karyotypes) and clinicopathological features was then investigated. Moreover, overall survival (OS) and progression-free survival (PFS) were analyzed to evaluate the predictive value of CTCs. RESULTS: The detection of CTCs using the NE-FISH approach helped in differentiating patients with EC from benign or healthy controls at a threshold of 2 per 3.2 ml peripheral blood with a sensitivity and specificity of 70.54% and 96.74%, respectively (area under the curve = 0.826, 95% CI 0.770–0.874, p < 0.001). The CTC count was associated with tumor depth (p = 0.012), but there was no correlation with other clinicopathological characteristics. Furthermore, the proportion of CTCs with chromosome 7 triploidy was linked to distant metastasis (p = 0.033) and TNM stage (p = 0.002). The OS was significantly shorter for patients with CTCs ≥ 3 than for those with CTCs < 3. Univariate analysis revealed that sex, vascular invasion, distant metastasis, tumor depth, lymph node metastasis, and TNM stage were the significant prognostic factors for patients with EC. Multivariate analysis demonstrated that distant metastasis (hazard ratio (HR) 3.262, 95% CI 1.671–6.369, p = 0.001 for PFS; HR 3.759, 95% CI 1.867–7.571, p < 0.001 for OS) was a significant prognostic factor for patients with EC. CONCLUSIONS: Detection of CTCs using NE-FISH could be helpful in the diagnosis of EC. The proportion of CTCs with chromosome 7 triploidy was related to distant metastasis and TNM stage. Patients with CTCs ≥ 3 had short OS, while distant metastasis was an independent factor indicating a poor prognosis for patients with EC. Frontiers Media S.A. 2022-03-21 /pmc/articles/PMC8977550/ /pubmed/35387131 http://dx.doi.org/10.3389/fonc.2022.828368 Text en Copyright © 2022 Li, Wang, Fu, Wang, Zhang, Tian and Yang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Yang
Wang, Zhenxing
Fu, Rao
Wang, Shuang
Zhang, Tingting
Tian, Xudong
Yang, Dawei
Clinical Utility of Circulating Tumor Cells in Patients With Esophageal Cancer
title Clinical Utility of Circulating Tumor Cells in Patients With Esophageal Cancer
title_full Clinical Utility of Circulating Tumor Cells in Patients With Esophageal Cancer
title_fullStr Clinical Utility of Circulating Tumor Cells in Patients With Esophageal Cancer
title_full_unstemmed Clinical Utility of Circulating Tumor Cells in Patients With Esophageal Cancer
title_short Clinical Utility of Circulating Tumor Cells in Patients With Esophageal Cancer
title_sort clinical utility of circulating tumor cells in patients with esophageal cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977550/
https://www.ncbi.nlm.nih.gov/pubmed/35387131
http://dx.doi.org/10.3389/fonc.2022.828368
work_keys_str_mv AT liyang clinicalutilityofcirculatingtumorcellsinpatientswithesophagealcancer
AT wangzhenxing clinicalutilityofcirculatingtumorcellsinpatientswithesophagealcancer
AT furao clinicalutilityofcirculatingtumorcellsinpatientswithesophagealcancer
AT wangshuang clinicalutilityofcirculatingtumorcellsinpatientswithesophagealcancer
AT zhangtingting clinicalutilityofcirculatingtumorcellsinpatientswithesophagealcancer
AT tianxudong clinicalutilityofcirculatingtumorcellsinpatientswithesophagealcancer
AT yangdawei clinicalutilityofcirculatingtumorcellsinpatientswithesophagealcancer